1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ndATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62 Annual Meeting of ...

VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a provider of compliant digital health infrastructure and on-demand healthcare services across the United States, today issued revenue guidance for the fiscal year ending December 31, 2026, and provided an outlook for the first quarter of fiscal 2026. Fiscal 2026 Revenue Guidance Based on current internal planning assumptions, the Company expects f ...

Core Viewpoint - Neurothera Labs Inc. has received a U.S. patent for its proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Company Summary - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics, particularly in the area of antimicrobial resistance [10]. - The company is a majority-owned subsidiary of SciSparc Ltd. [1]. Technology and Innovation - The patented technology combines established antibiotics with cannabinoids like THC and CBD, demonstrating enhanced antimicrobial activity against resistant pathogens such as MRSA in preclinical studies [3][5]. - The platform aims to restore the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens [3]. Market Context - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The emergence of resistant bacterial strains, particularly MRSA, has led to a significant increase in healthcare-acquired infections, with a reported 30% rise in the U.S. [6]. Antimicrobial Resistance Challenge - Prolonged antibiotic use has resulted in the emergence of resistant strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, more than double the 57,000 deaths in 2019 [4]. - Overall, bacterial antimicrobial resistance caused 1.14 million deaths and was associated with 4.71 million deaths globally in 2021 [4]. Industry Dynamics - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to high costs and lengthy development timelines, leading to a gap in innovation as major firms exit the field [8][9]. - The need for innovative solutions that enhance the efficacy of existing antibiotics while improving safety is critical in the current landscape of antimicrobial resistance [6][7].

Core Insights - The article emphasizes the importance of looking beyond well-known companies to discover undervalued and well-managed organizations that can yield strong returns [1]. Group 1 - The lead analyst for Dividend Kings, Scott Kaufman, has over a decade of experience in the financial sector and focuses on identifying high-quality dividend-growing and undervalued investment opportunities [2]. - The goal of the analysis is to achieve a robust total return through cash dividends and strong capital gains [2].

Salt Lake City, Utah--(Newsfile Corp. - February 2, 2026) - OneMeta (OTCQB: ONEI) will provide near-instantaneous multilingual translation services at next week's Silicon Slopes SUMMIT, marking the first time such services will be offered during SUMMIT 2026.Held February 4-7 at Salt Lake City's Salt Palace Convention Center, SUMMIT has drawn as many as 24,000 attendees and is one of the largest technology conferences in the country.During SUMMIT 2026, OneMeta will deploy VerbumOnSite™, its AI-powered, real ...

Group 1 - Giverny Capital Asset Management reported a portfolio return of 0.01% for Q4 2025, underperforming the S&P 500 which returned 2.66% [1] - Year-to-date, the fund achieved a return of 12.58%, compared to 17.88% for the S&P 500 [1] - The portfolio's underweight in large technology companies and overweight in smaller niche leaders negatively impacted performance, despite strong earnings growth and capital returns from portfolio companies [1] Group 2 - AMETEK, Inc. (NYSE:AME) stock closed at $223.98 per share on January 30, 2026, with a one-month return of 6.00% and a twelve-month gain of 21.64% [2] - AMETEK, Inc. has a market capitalization of $51.56 billion [2] - Giverny Capital Asset Management trimmed its position in AMETEK, citing valuation concerns, as the stock became expensive relative to its growth rate [3] Group 3 - AMETEK, Inc. was held by 58 hedge fund portfolios at the end of Q3 2025, an increase from 53 in the previous quarter [3] - While AMETEK is recognized for its potential, the company is not among the 30 most popular stocks among hedge funds [3] - The firm believes certain AI stocks present greater upside potential and less downside risk compared to AMETEK [3]

Tenable's stock (NASDAQ:TENB) has declined more than 44% over the past few months, and the selling pressure has accelerated as the stock moves deeper into its current structural window. On the weekly charts, TENB is now in Phase 10 of its 18-phase Adhishthana cycle. When viewed through this framework, the recent weakness does not appear random. Instead, it reflects a larger structural shift that investors should take seriously. Here's why the stock should not be viewed as a value opportunity, at least for n ...

Core Insights - Giverny Capital Asset Management's portfolio returned 0.01% in Q4 2025, underperforming the S&P 500's 2.66% return, and year-to-date returns were 12.58% compared to the index's 17.88% [1] - The firm faced challenges due to the outperformance of large technology companies, which negatively impacted the portfolio's performance due to its underweight in large tech and overweight in smaller niche leaders [1] - Despite strong earnings growth and capital returns from portfolio companies, the market's focus on AI investments has created uncertainty regarding actual benefits [1] Company Highlights - Hawkins, Inc. (NASDAQ:HWKN) was highlighted as a new holding in Giverny Capital Asset Management's Q4 2025 investor letter [2] - Hawkins, Inc. specializes in manufacturing ingredients for water treatment, food and health applications, and industrial use, with a market capitalization of approximately $2.722 billion [2] - The stock closed at $130.25 per share on January 30, 2026, with a one-month return of 13.20% and a twelve-month gain of 15.77% [2] - The company was closely monitored by Giverny Capital, with management visits conducted in the summer of 2024, and a price correction in fall 2025 provided an opportunity for investment [3]

Core Insights - The company reported a net sales increase of 6.8% on a constant currency basis, with diluted earnings per share rising from $3.00 to $3.33 [1] Group 1: Brand Performance - HOKA brand revenue increased by 18.5%, totaling $628.9 million, while UGG brand sales rose by 4.9% to $1.305 billion [2] - Other brands experienced a significant decline of 55.5% in sales, falling to $23.2 million, partly due to the phase-out of Koolaburra brand operations [2] Group 2: Distribution Channels - Wholesale net sales increased by 6% to $864.6 million, while direct-to-consumer (DTC) net sales rose by 8.1% to $1.093 billion, with DTC comparable net sales up by 7.3% [3] - Domestic sales grew by 2.7% to $1.2 billion, while international sales saw a substantial increase of 15%, reaching $756.7 million [3] Group 3: Financial Metrics - Gross margin slightly decreased from 60.3% to 59.8%, while selling, general, and administrative expenses rose to $557 million from $535.3 million [4] - Operating income improved from $567.3 million to $614.4 million [4] - As of 31 December 2025, the company held cash and cash equivalents of $2.087 billion and inventories of $633.5 million, with no outstanding borrowings [4] Group 4: Capital Allocation - During the third fiscal quarter, the company repurchased approximately 3.8 million shares for $348.5 million at an average price of $92.36 per share [5] - Over the first nine months of fiscal year 2026, around eight million shares were bought back for a total of $813.5 million at an average price of $101.44 per share [5] Group 5: Future Outlook - For the full fiscal year ending 31 March 2026, the company projects net sales between $5.400 billion and $5.425 billion, with mid-teens percentage growth anticipated for HOKA and mid-single-digit increases for UGG compared to last year [6] Group 6: Management Commentary - The CEO attributed positive results to strategic initiatives and effective marketplace management, highlighting significant growth for HOKA in both US and international markets [7] - The CEO emphasized balanced growth in DTC and wholesale channels, with strong gross margins driven by high levels of full-price selling for both UGG and HOKA [8]

Group 1 - The new trading range is expected to be between $5002.31 and $5143.89, with traders facing a decision to either short or anticipate a breakout if this zone is tested [1][2] - A significant sell-off occurred due to a combination of speculative trading and external factors, including the nomination of Kevin Warsh for the U.S. Federal Reserve Chair and a lack of clarity on rate cuts from the Fed [4] - The market's long-term outlook remains bullish, but the rapid rise driven by speculators has led to a correction, indicating a need for a support base to form above the 50-day moving average to attract real buyers [3][4] Group 2 - The first leg down from a major top is typically characterized by long liquidation, followed by a retracement of 50% to 61.8% of the previous move, with aggressive shorts likely to enter at the retracement zone [2] - If the retracement zone is breached, it may signal the return of buyers, while holding at this level indicates the presence of sellers [2]